Europe’s biotech future was a central theme for ExecMind at Prague.bio 2026 - a day of international perspectives, valuable conversations and discussion about how to turn scientific strengths into globally competitive businesses.
Held on 23 September at the National House Vinohrady in Prague, the fourth edition of the conference brought together biotechnology companies, researchers, investors and industry experts. The programme explored global biotech trends, investment, technology transfer and the development of emerging companies.
A Forward-Looking View of European Biotechnology
One of the highlights was the contribution from Claire Skentelbery, Director General of EuropaBio, whose presentation addressed whether Europe can close the biotech competitiveness gap. The programme also examined Europe’s position alongside the US, China and other Asian markets.
For us, the strongest takeaway was the confidence behind that discussion: Europe has significant strengths to build on, and the focus should be on putting them to work.
Rather than looking back at past achievements, we left the session thinking about what Europe can achieve next and what it will take to get there.
From ExecMind’s perspective, leadership is an essential part of that ambition. Building internationally competitive biotech companies requires people who can connect scientific progress with investment, partnering and commercial development. This is particularly relevant for emerging businesses across Central and Eastern Europe as they pursue opportunities beyond their home markets.
That combination of substantive discussion and personal connection is an important reason for ExecMind to participate in events such as Prague.bio.
We thank Petra Kinzlová and the entire Prague.bio team for their thoughtful organisation and attention to detail, from the programme to the welcoming atmosphere.
https://prague.bio/conference-2026/
